Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 16.2% in February

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 8,090,000 shares, a decrease of 16.2% from the February 13th total of 9,650,000 shares. Approximately 6.5% of the shares of the company are short sold. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is currently 7.0 days.

Lyell Immunopharma Trading Up 20.3 %

NASDAQ:LYEL traded up $0.10 during trading hours on Wednesday, hitting $0.58. 2,315,737 shares of the stock were exchanged, compared to its average volume of 1,044,535. The company has a market cap of $171.76 million, a P/E ratio of -0.74 and a beta of -0.41. The firm’s fifty day moving average price is $0.62 and its 200 day moving average price is $0.89. Lyell Immunopharma has a 52-week low of $0.48 and a 52-week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.01 million during the quarter. Equities analysts expect that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, CFO Charles W. Newton acquired 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the transaction, the chief financial officer now directly owns 200,000 shares of the company’s stock, valued at $112,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Klausner bought 158,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The shares were acquired at an average cost of $0.60 per share, with a total value of $94,800.00. Following the completion of the purchase, the director now owns 843,365 shares in the company, valued at approximately $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 533,000 shares of company stock valued at $313,550. 25.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently bought and sold shares of LYEL. Barclays PLC boosted its holdings in shares of Lyell Immunopharma by 7.4% during the 4th quarter. Barclays PLC now owns 258,380 shares of the company’s stock worth $165,000 after purchasing an additional 17,765 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock worth $60,000 after buying an additional 20,542 shares during the last quarter. Centiva Capital LP purchased a new stake in Lyell Immunopharma in the third quarter valued at $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Lyell Immunopharma by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock valued at $197,000 after buying an additional 36,555 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Lyell Immunopharma in the 3rd quarter worth approximately $52,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.